Gilad Aharon, director of Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) (TSXV:TTI), bought 499,000 Common Shares on the open market at an average of $0.51, a $254K purchase on Sep 22, 2026, disclosed Sep 23, 2026.
The purchase increased the holding through Rosalind Master Fund L.P. by about 12%. Aharon now holds 4,649,500 shares through Rosalind Master Fund L.P., worth about $2.6M at the Sep 23, 2026 close.
TTI closed at $0.56 on Sep 23, 2026. In the 52 weeks to that date it closed between $0.44 and $0.77, and that close was 27% below the high. The average price was 8.9% below the Sep 22, 2026 close.
